| 包装: | 20mg |
| 市场价: | 1869元 |
Calycosin (CA, 7, 3-dihydroxy-4-methoxy isoflavone, C16H12O5) is one of the flavonoids extracted from astragalus root, also known as the typical phytoestrogens.
Cell lines | MCF-7 and T47D cells |
Preparation Method | MCF-7 and T47D cells were cultured and treated in triplicate with various doses (0, 6.25, 12.5, 25, 50, 100 and 150 µM) of calycosin for 48 h. |
Reaction Conditions | 0- 150 µM calycosin for 48 h |
Applications | Treatment with Calycosin lower doses (6.25 or 12.5 µM) promoted proliferation of breast cancer cells, but with higher doses significantly reduced the viability of MCF-7 and T47D cells. |
Animal models | MG-63 tumor-bearing nude mice(eight weeks-of-age, weighing between 17-22 g) |
Preparation Method | Ten days after implantation of the GM-63 cells, when tumors were seen to develop, mice were randomly divided into five groups: a control group, an ifosfamide-treated group (4mg/kg), and three calycosin-treated groups (2, 4, and 8 mg/kg)treated by intraperitoneal injection. Calycosin and ifosfamide were injected daily for 15 days. |
Dosage form | 2, 4, and 8 mg/kg calycosin for 15 days |
Applications | In the nude mouse MG-63 tumor xenografts, calycosin inhibited tumor growth and regulated the expression levels of apoptosis-related PI3K/AKT/mTOR pathway proteins. |
| 文献引用 | |
| 产品描述 | Calycosin (CA, 7, 3-dihydroxy-4-methoxy isoflavone, C16H12O5) is one of the flavonoids extracted from astragalus root, also known as the typical phytoestrogens[1,2]. Calycosin is widely used in the pharmaceutical and food fields, and likely to be taken at low or high doses in daily life[3]. Treatment with Calycosin lower doses (6.25 or 12.5 μM) promoted proliferation of breast cancer cells, but with higher doses significantly reduced the viability of MCF-7 and T47D cells. Furthermore, higher doses of calycosin were found to inhibit migration and invasion of the two cell lines in a dose-dependent manner[4]. Calycosin induced apoptosis of osteosarcoma cells (143B) via increasing caspase-3 protein levels, reducing intracellular Bcl-2B-cell lymphoma 2 (Bcl-2) protein expression and up-regulating apoptotic protease activating factor-1 (Apaf-1) in tumors[5]. Moreover, Calycosin induced apoptosis of osteosarcoma cells through the dose-dependent reducing proliferating cell nuclear antigen and the expression of Bcl-2, and increasing the cleavage of Poly (ADP-ribose) polymerase (PARP)[7]. Calycosin also has antioxidant properties (SC50 = 42.53±1.77 μg/mL)[9]. In estrogen receptor (ER)-positive MG-63 human osteosarcoma cells and MG-63 tumor-bearing nude mice, Calycosin induced apoptosis of osteosarcoma cells by increasing the expression of the phosphorylated-phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway proteins[6]. Calycosin can play an anti-inflammatory role by binding with IL-6. Calycosin inhibited kidney inflammation caused by diabetes by inhibiting the phosphorylation of IκBα and nuclear factor κB (NF-κB)/p65 in vitro and in vivo[8]. References: |
m.cnreagent.com